Tag: MONOGRAPH

  • Citrus-Bergamot

    Polyphenol-rich Citrus flavonoid extract with AMPK-activating, hypolipidemic, and insulin-sensitizing activity

    A standardized polyphenolic extract derived from Citrus bergamia Risso & Poiteau, distinguished by the presence of the 3-hydroxy-3-methylglutaryl (HMG)-conjugated flavanones brutieridin and melitidin, and investigated for cardiovascular risk factor modification through pleiotropic lipid-lowering, glycemic, hepatoprotective, and anti-inflammatory mechanisms.

    Abstract

    Citrus bergamot extract, derived from the juice and albedo of the bergamot orange (Citrus bergamia Risso & Poiteau), is a polyphenol-rich botanical preparation whose pharmacological interest centers on a distinctive flavonoid profile that includes the 3-hydroxy-3-methylglutaryl (HMG)-conjugated flavanone glycosides brutieridin and melitidin, alongside high concentrations of neoeriocitrin, naringin, and neohesperidin. These HMG-bearing flavanones are structurally analogous to the HMG-CoA substrate of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis and the molecular target of statin drugs. In vitro mechanistic studies in HepG2 and Caco-2 cell lines have demonstrated that bergamot polyphenolic fraction (BPF) and its principal constituents reduce HMGCR protein levels, activate AMP-activated protein kinase (AMPK) phosphorylation, stimulate fatty acid oxidation, and inhibit intestinal cholesterol absorption through downregulation of the Niemann-Pick C1-Like 1 (NPC1L1) transporter. The mechanism is therefore distinct from direct competitive HMGCR inhibition by statins and involves transcriptional and post-translational regulation of cholesterol biosynthetic and absorptive pathways.

    Clinical investigation of bergamot polyphenolic extracts has been conducted primarily in Southern Italian populations with hyperlipidemia, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD). A 2020 randomized trial of a bergamot-cardoon combination (Bergacyn) in NAFLD patients over 50 years demonstrated significant reductions in liver steatosis, body weight, and hepatic transaminases.

    The pharmacokinetic profile of bergamot flavonoids in humans is incompletely characterized. Oral consumption produces circulating phase II conjugated metabolites (sulfates and glucuronides of naringenin, hesperetin, and eriodictyol) detectable at 1 and 4 hours post-ingestion, consistent with intestinal deglycosylation and hepatic phase II conjugation. The characteristic HMG-conjugated flavanones brutieridin and melitidin have not been detected in plasma or urine in published pharmacokinetic studies, raising the possibility that their hypolipidemic activity is mediated locally in the gastrointestinal epithelium or through metabolites not yet characterized. The extract is generally well tolerated in clinical studies of up to 24 weeks duration, with adverse events limited to mild gastrointestinal discomfort in a minority of subjects. Bergamot contains furanocoumarins (bergamottin, bergapten) that inhibit CYP3A4, producing clinically relevant interactions with statins metabolized by this isoform (atorvastatin, simvastatin, lovastatin) and other CYP3A4 substrates. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Ibogainalog

    Non-selective serotonin receptor modulator, psychoplastogen, and ibogaine-derived tricyclic azepinoindole analog

    A simplified tricyclic ibogaine analog and potent 5-HT2A receptor agonist with psychoplastogenic, antidepressant, and analgesic activity, distinguished from the parent iboga alkaloids by dramatically reduced cardiotoxicity, absence of opioid receptor engagement, and retained promotion of structural neural plasticity.

    Abstract

    Ibogainalog (IBG; 9-methoxy-3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indole; CAS 802581-10-8) is a synthetic tricyclic azepinoindole and a structurally simplified analog of the iboga alkaloid ibogaine, first described in the chemical literature by Hester and colleagues in the late 1960s and subsequently characterized in pharmacological detail by the Olson laboratory at the University of California, Davis, beginning in 2020. The compound belongs to the ibogalog structural class, a family of substituted hexahydroazepino[4,5-b]indoles that retain the fused indole-azepine core of the iboga alkaloids while eliminating the isoquinuclidine ring system, yielding a dramatically simplified molecular architecture that is amenable to practical gram-scale synthesis. Ibogainalog is a non-selective serotonin receptor modulator with potent agonist activity at the 5-HT2A receptor (Ki approximately 670 nM; functional EC50 18 to 85 nM, 55 to 93 percent efficacy), the 5-HT6 receptor (EC50 7.1 to 8.8 nM, 83 to 99 percent efficacy), the 5-HT1F receptor (EC50 35 nM, 85 percent efficacy), and the 5-HT1B receptor (EC50 170 nM, 76 percent efficacy), with additional inverse agonist activity at the 5-HT7 receptor (EC50 335 nM) and mixed agonist-antagonist activity at the 5-HT2B and 5-HT2C receptors. The compound is a moderate serotonin reuptake inhibitor (SERT IC50 approximately 400 nM) with selectivity over the norepinephrine and dopamine transporters, and a noncompetitive inhibitor of the alpha-7 nicotinic acetylcholine receptor (IC50 approximately 11.4 micromolar) and a competitive inhibitor of the alpha-9-alpha-10 nicotinic acetylcholine receptor (IC50 approximately 2.9 micromolar). Critically, ibogainalog exhibits dramatically reduced potency at the hERG potassium channel relative to ibogaine (approximately 10-fold reduction), conferring a substantially improved cardiac safety profile; this is a principal design objective of the ibogalog class, given that ibogaine-associated QT prolongation and fatal cardiac arrhythmias have been a central safety concern limiting the clinical translation of ibogaine itself. The compound shows no agonist activity at opioid receptors, distinguishing it from the active ibogaine metabolite noribogaine. In preclinical behavioral models, ibogainalog at 10 mg/kg produces sustained antidepressant-like activity (persisting 72 hours in naive mice and 48 hours in chronically stressed mice) through a volinanserin-sensitive, 5-HT2A receptor-dependent serotonergic mechanism. The compound also produces dose-dependent antinociceptive activity in chronic constriction injury models of neuropathic pain and in dextran sulfate sodium-induced colitis models of visceral pain, with the longest anti-hyperalgesic duration among tested ibogalogs at comparatively lower doses. Analgesic activity is abolished by the 5-HT2A receptor antagonist ketanserin and involves synergistic crosstalk between 5-HT2A and metabotropic glutamate type 2 (mGlu2) receptors. As a psychoplastogen, ibogainalog promotes dendritic arborization and spinogenesis in cortical neurons at levels comparable to ibogaine, an activity mediated through 5-HT2A receptor signaling. Unlike the closely related ibogalog tabernanthalog, ibogainalog produces a measurable head-twitch response in rodent models, suggesting that it may retain psychedelic activity in humans, though the response magnitude is substantially reduced relative to classical psychedelics such as 5-methoxy-N,N-dimethyltryptamine. The compound is not in clinical development as of the date of this monograph; all evidence is preclinical. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Setipiprant

    Selective CRTH2 (prostaglandin D2 receptor 2/DP2) antagonist of the tetrahydropyridoindole structural class

    A potent, orally bioavailable tetrahydropyridoindole antagonist of the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2/DP2), developed at Actelion as an anti-inflammatory candidate for allergic asthma and seasonal allergic rhinitis and subsequently repositioned by Kythera Biopharmaceuticals for androgenetic alopecia on the basis of the Garza et al. (2012) demonstration that prostaglandin D2 is elevated in the bald scalp of men with male pattern hair loss.

    Abstract

    Setipiprant (ACT-129968, KYTH-105) is a tetrahydropyridoindole derivative that acts as a potent, selective, and orally bioavailable antagonist of the chemoattractant receptor-homologous molecule expressed on T-helper 2 cells (CRTH2), also designated as the prostaglandin D2 receptor 2 (DP2 or GPR44). The compound binds the human CRTH2 receptor with an IC50 of approximately 6 nanomolar and demonstrates approximately 215-fold selectivity over the prostaglandin D2 receptor 1 (DP1), with no meaningful antagonism of the thromboxane receptor or inhibition of cyclooxygenase-1. CRTH2 is a G-protein-coupled receptor expressed on eosinophils, basophils, type 2 innate lymphoid cells, and T-helper 2 lymphocytes; activation by prostaglandin D2 drives chemotaxis, degranulation, and cytokine release from these cells, positioning CRTH2 antagonism as a mechanistically distinct anti-inflammatory strategy in allergic and type 2 inflammatory disease.

    Setipiprant was discovered at Actelion Pharmaceuticals through a lead optimization program focused on improving potency and oral bioavailability within a pyrido[4,3-b]indole scaffold series. The compound advanced through Phase 1 single- and multiple-ascending-dose studies demonstrating favorable tolerability, rapid oral absorption (time to peak concentration approximately 2 to 4 hours), a terminal elimination half-life of 10 to 18 hours, and near-complete recovery of administered radioactivity in a human mass balance study (approximately 88 percent fecal, 12 percent urinary). Approximately 54 percent of administered dose was recovered as unchanged parent compound, indicating that direct fecal excretion rather than hepatic metabolism is the dominant clearance pathway. The two principal circulating metabolites, M7 and M9, are dihydroxy-dihydronaphthalene isomers formed through epoxidation of the naphthyl ring, and neither exceeds 10 percent of parent drug plasma concentrations at steady state.

    Actelion advanced setipiprant through Phase 2 and Phase 3 clinical programs in seasonal allergic rhinitis and a Phase 2a proof-of-mechanism study in allergic asthma. However, the Phase 3 confirmatory trial (n=630) at the same dose failed to replicate the Phase 2 efficacy signal on the primary endpoint (p=0.652), despite adequate methodology and a consistent cetirizine active-reference effect. Actelion discontinued development in the allergic rhinitis and asthma indications and redirected anti-inflammatory efforts to a follow-up CRTH2 antagonist.

    The compound was subsequently repositioned for androgenetic alopecia following the Garza et al. (2012) demonstration in Science Translational Medicine that prostaglandin D2 synthase and prostaglandin D2 are elevated in the bald scalp of men with androgenetic alopecia and that prostaglandin D2 inhibits hair follicle growth through the CRTH2/GPR44 receptor. Kythera Biopharmaceuticals acquired the rights to setipiprant and submitted an Investigational New Drug application to the FDA in September 2015 (designated KYTH-105). The trial did not meet either coprimary endpoint: target area hair count change was 6.7 hairs per square centimeter with setipiprant versus 7.0 with placebo (p=0.92), and subject self-assessment showed no difference (p=0.91). Setipiprant was well tolerated throughout all clinical programs, with headache as the most frequently reported adverse event and no severe or clinically significant safety signals identified across more than 1,500 subjects exposed in clinical trials.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cogitum

    Acetylated amino acid derivative; synthetic N-acetylaspartate analog with neurometabolic and adaptogenic activity

    A potassium salt of N-acetyl-DL-aminosuccinic acid developed in France as an oral neurometabolic tonic for asthenic syndrome, cognitive fatigue, and pediatric neurodevelopmental delay, distinguished by its structural relationship to endogenous N-acetylaspartate and downstream modulation of glutamatergic and myelinogenic pathways.

    Abstract

    Cogitum is the proprietary pharmaceutical preparation of potassium N-acetyl-DL-aminosuccinate (bipotassium acetylaminosuccinate), a synthetic analog of N-acetylaspartate (NAA), the most concentrated free amino acid derivative in the mammalian central nervous system. The compound was developed in France and patented in the United States in 1969 (US 3,433,875) for the improvement of mental performance in adults experiencing intellectual overwork, memory disorders, and cognitive decline associated with senescence. The active substance provides an exogenous source of the acetylated aspartate moiety that participates in neuronal energy metabolism through the tricarboxylic acid cycle, serves as the obligate precursor for myelin lipid synthesis via oligodendrocytic aspartoacylase-mediated deacetylation, functions as an osmolyte maintaining neuronal volume homeostasis, and is the direct biosynthetic precursor of N-acetylaspartylglutamate (NAAG), the most abundant neuropeptide in the human brain and an endogenous agonist at the presynaptic metabotropic glutamate receptor type 3 (mGluR3).

    Pediatric evidence comprises a 249-patient study in children with ADHD and subclinical epileptiform electroencephalographic activity demonstrating significant improvements in attention, memory, and speech without aggravation of epileptiform discharges or provocation of seizures; additional cohort studies in children with speech delay, traumatic brain injury sequelae, mental retardation, and schizotypal spectrum disorders have reported efficacy in improving cognitive and linguistic performance. The pharmacological rationale rests on the established neurobiology of endogenous N-acetylaspartate: NAA concentrations in the brain reach 10 millimolar or greater, are confined almost exclusively to neurons, and serve as the principal magnetic resonance spectroscopy marker of neuronal viability; reduced NAA is a consistent finding in neurodegenerative disease, traumatic brain injury, multiple sclerosis, and neurodevelopmental disorders. The exogenous provision of the acetylaminosuccinate moiety is hypothesized to support neuronal mitochondrial energy production, to provide acetate substrate for oligodendrocytic myelin lipid synthesis, and to augment NAAG-mediated glutamatergic neuromodulation.

    Safety data across pediatric and adult populations demonstrate excellent tolerability. The compound has no reported cases of overdose toxicity, produces no clinically significant drug interactions at registered doses, and is contraindicated only in cases of known hypersensitivity to the active substance or excipients. The principal limitation of the evidence base is the concentration of clinical research in Russian-language journals with limited replication in Western multicenter trial frameworks. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Isotretinoin

    First-generation retinoid (13-cis-retinoic acid) with sebosuppressive, pro-apoptotic, anti-keratinizing, and immunomodulatory activity

    A systemic retinoid derived from vitamin A, developed at Hoffmann-La Roche as a treatment for severe recalcitrant nodular acne, distinguished from other retinoids by potent sebaceous gland suppression through sebocyte apoptosis, intracellular isomerization to all-trans retinoic acid, and additional clinical utility in high-risk neuroblastoma maintenance therapy.

    Abstract

    Isotretinoin (13-cis-retinoic acid) is a first-generation retinoid and geometric isomer of all-trans retinoic acid (tretinoin) that was approved by the United States Food and Drug Administration on 7 May 1982 under the trade name Accutane for the treatment of severe recalcitrant nodular acne unresponsive to conventional therapies including systemic antibiotics. Unlike topical retinoids that act through direct binding to retinoic acid receptors (RARs) at the site of application, isotretinoin functions as a systemic pro-drug: despite exhibiting low intrinsic affinity for both RAR and retinoid X receptor (RXR) nuclear receptors, the compound undergoes intracellular isomerization to all-trans retinoic acid in sebocytes and other target tissues, with the active isomer then binding RARs and driving transcriptional programs that suppress sebogenesis, normalize follicular keratinization, and induce apoptosis in sebaceous gland cells [3, 4]. The four principal pharmacological actions that underwrite clinical efficacy in acne are: (a) marked reduction in sebaceous gland size and sebum production (up to 90 percent suppression), mediated by FoxO3a-dependent and TRAIL/caspase-mediated apoptosis of sebocytes; (b) normalization of aberrant follicular keratinization, reducing comedone formation; (c) indirect suppression of Cutibacterium acnes colonization secondary to the reduction in the lipid-rich sebaceous microenvironment; and (d) anti-inflammatory and immunomodulatory activity, including downregulation of Toll-like receptor 2 (TLR-2) signaling and NF-kappaB-dependent cytokine production in monocytes and keratinocytes [5, 6, 7].

    Pharmacokinetics are characterized by variable oral bioavailability that is markedly enhanced by co-administration with a high-fat meal (approximately twofold increase in area under the curve), extensive plasma protein binding (greater than 99.9 percent to albumin), hepatic metabolism principally through CYP2C8, CYP3A4, CYP2C9, and CYP2B6 to the major circulating metabolite 4-oxo-isotretinoin, and a terminal elimination half-life of 10 to 20 hours for the parent compound and up to 50 hours for the 4-oxo metabolite [8, 9]. The compound undergoes enterohepatic recirculation, contributing to sustained plasma concentrations during chronic dosing.

    The compound has also been studied in disorders of keratinization (lamellar ichthyosis, Darier disease), rosacea, prevention of second primary tumors in head and neck squamous cell carcinoma, and glioblastoma multiforme, though these applications have not produced registrational-quality evidence sufficient for label expansion.

    The safety profile of isotretinoin is dominated by two categories of concern. The first and most clinically significant is teratogenicity: isotretinoin is classified as FDA Pregnancy Category X, with an estimated 20 to 35 percent risk of major congenital malformations in exposed pregnancies, including craniofacial, cardiovascular, thymic, and central nervous system defects [11]. This risk led to the implementation of the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program in the United States in 2006, which mandates pregnancy testing, dual contraception, and monthly verification for all patients of childbearing potential [12]. Additional safety signals include dose-dependent hypertriglyceridemia, transaminase elevation, musculoskeletal complaints (myalgia, arthralgia), and a contested but pharmacovigilance-supported association with psychiatric adverse events including depression, though large epidemiological studies have not established a causal relationship [13, 14]. The association with inflammatory bowel disease has been examined in multiple studies with conflicting results; the most rigorous analyses suggest the incidence is extremely low and the causal link remains unproven [15].

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Suzetrigine

    Selective NaV1.8 voltage-gated sodium channel inhibitor (non-opioid peripheral analgesic)

    A first-in-class, peripherally restricted NaV1.8 sodium channel inhibitor developed by Vertex Pharmaceuticals as a non-opioid analgesic for moderate-to-severe acute pain, distinguished by allosteric binding to voltage-sensing domain 2 and greater than 31,000-fold selectivity over all other sodium channel subtypes.

    Abstract

    Suzetrigine (VX-548; trade name Journavx) is the first selective inhibitor of the NaV1.8 voltage-gated sodium channel to receive regulatory approval, granted by the United States Food and Drug Administration on 30 January 2025 for the treatment of moderate-to-severe acute pain in adults. The compound represents a mechanistically novel analgesic class, acting by allosteric binding to the extracellular S3-S4 loop of voltage-sensing domain 2 (VSD2) of the NaV1.8 channel, where a KKGS amino acid sequence unique to this subtype confers greater than 31,000-fold selectivity over the other nine human voltage-gated sodium channel isoforms. NaV1.8, encoded by the SCN10A gene, is expressed almost exclusively in peripheral nociceptive neurons of the dorsal root ganglia, where it contributes more than 70 percent of the depolarizing current during pain-signaling action potentials. Suzetrigine stabilizes the channel in its closed (resting) state through tonic inhibition that is independent of channel opening frequency, thereby reducing pathological nociceptor hyperexcitability without affecting cardiac, central nervous system, or skeletal muscle sodium channels.

    The compound emerged from a multi-year medicinal chemistry program at Vertex Pharmaceuticals that progressed through the predecessors VX-128 and VX-150 before arriving at VX-548, which demonstrated an in vitro IC50 of 0.68 nanomolar against human NaV1.8 with negligible activity (IC50 greater than 10,000 nanomolar) against all other NaV subtypes. In the pivotal Phase 3 NAVIGATE-1 (bunionectomy, N = 1,073) and NAVIGATE-2 (abdominoplasty, N = 1,118) trials, suzetrigine achieved statistically significant superiority over placebo on SPID48 (p = 0.0002 and p < 0.0001, respectively), with analgesic efficacy broadly comparable to hydrocodone/acetaminophen but without opioid-class adverse effects including respiratory depression, sedation, or abuse liability.

    Pharmacokinetics are characterized by oral administration with a time to peak plasma concentration of approximately 3 hours in the fasted state, extensive tissue distribution (volume of distribution approximately 495 liters), 99 percent plasma protein binding, and hepatic metabolism predominantly through CYP3A enzymes to the active metabolite M6-SUZ (3.7-fold less potent than parent compound). Excretion occurs through both fecal (49.9 percent) and urinary (44.0 percent) routes. The compound is contraindicated with strong CYP3A4 inhibitors and in severe hepatic impairment (Child-Pugh Class C). The most common adverse events in clinical trials were nausea, headache, dizziness, constipation, pruritus, muscle spasms, and rash, all predominantly mild to moderate in severity. No respiratory depression, physical dependence, or abuse potential has been identified in clinical or preclinical assessments.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • CT1812

    Selective sigma-2 receptor (TMEM97) complex antagonist with anti-amyloid-beta oligomer synaptoproctective activity

    A first-in-class, orally bioavailable isoindoline sigma-2 receptor antagonist developed by Cognition Therapeutics to displace amyloid-beta oligomers from neuronal synapses, with Phase 2 clinical evidence of cognitive benefit in Alzheimer’s disease and dementia with Lewy bodies.

    Abstract

    CT1812 (zervimesine; CAS 1802632-22-9) is a first-in-class, orally bioavailable small-molecule antagonist of the sigma-2 receptor complex (also designated TMEM97, transmembrane protein 97) developed by Cognition Therapeutics for the treatment of Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and geographic atrophy secondary to dry age-related macular degeneration. The compound was identified through a phenotypic neuronal screening assay designed to detect reversal of amyloid-beta oligomer (ABO) induced synaptotoxicity and was chemically optimized from a series of isoindoline scaffolds selected for central nervous system penetration, metabolic stability, and selectivity against cardiac ion channel (hERG) liability. CT1812 binds the sigma-2 receptor with a Ki of 8.5 nM and demonstrates greater than 100-fold selectivity over a broad receptor panel, with approximately 10-fold selectivity over the sigma-1 receptor. The mechanism of action is allosteric antagonism of the sigma-2 receptor complex, which includes TMEM97, progesterone receptor membrane component 1 (PGRMC1), and low-density lipoprotein receptor (LDLR) at the neuronal surface. Engagement of this complex by CT1812 induces a conformational change that displaces prebound amyloid-beta oligomers from synaptic receptors without affecting oligomer assembly or dissociation, thereby restoring synaptic trafficking, reducing synaptotoxicity, and facilitating clearance of oligomers into the cerebrospinal fluid.

    In preclinical studies, CT1812 demonstrated robust brain penetration (brain-to-plasma ratio of 5.7 at 24 hours; unbound brain-to-plasma partition coefficient Kp,uu of 6.75), achieved greater than 84 percent sigma-2 receptor occupancy at therapeutically relevant doses, and improved cognitive performance in transgenic Alzheimer’s mouse models across Y-maze, Morris water maze, and fear conditioning paradigms. The compound is not a P-glycoprotein substrate, exhibits favorable oral absorption with time to peak plasma concentration of 1 to 2 hours and a plasma elimination half-life of approximately 12 hours in humans, and is metabolized primarily by CYP3A4 with secondary contributions from CYP2D6 and CYP2C19.

    A Phase 1b/2 trial (COG0102) in 19 patients with mild to moderate AD demonstrated reductions in cerebrospinal fluid synaptic damage markers (neurogranin and synaptotagmin-1) and decreases of 30 percent or more in six tau phosphorylation sites after 28 days of treatment. The Phase 2 SHIMMER trial (COG1201) enrolled 130 patients with mild to moderate DLB and met its primary safety endpoint; secondary analyses showed 82 percent of treated patients demonstrated slowing on the total Neuropsychiatric Inventory, with a 91 percent reduction in decline of attentional fluctuation measures. CT1812 has also been evaluated in the Phase 2 MAGNIFY trial for geographic atrophy, where treated patients showed 28.6 percent slower lesion growth over 18 months compared to placebo. CT1812 is positioned for Phase 3 development in Alzheimer’s disease. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Itruvone

    Synthetic pregnane neuroactive steroid vomeropherine acting via nasal chemosensory receptor activation of olfactory-amygdala neural circuits

    A synthetic pregnane steroid pherine developed by Pherin Pharmaceuticals and advanced by VistaGen Therapeutics as an intranasal microgram-dose nasal spray for major depressive disorder, distinguished from all approved antidepressants by a proposed non-systemic mechanism of action operating through peripheral nasal chemosensory neuron activation of limbic-hypothalamic catecholaminergic circuits without requirement for blood-brain barrier penetration or direct central nervous system receptor engagement.

    Abstract

    Itruvone (PH10; pregn-4-en-20-yn-3-one; CAS 21321-89-1) is a synthetic neuroactive steroid of the pregnane class and the second clinical-stage pherine (vomeropherine) molecule, under development by VistaGen Therapeutics as an intranasal nasal spray for the treatment of major depressive disorder (MDD). The compound is structurally characterized by a 17-alpha-ethynyl substituent on the pregnane steroid nucleus and a 3-keto-4-ene A-ring motif, yielding an odorless crystalline material with a molecular weight of 296.45 g/mol and the molecular formula C21H28O. Itruvone is pharmacologically distinguished from all currently approved antidepressants, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and the rapid-onset agents esketamine and brexanolone, by a proposed mechanism of action that does not require systemic absorption or direct activity on neuronal receptors in the brain.

    Preclinical tissue distribution studies using radiolabeled [14C]PH10 in rats demonstrated that a single intranasal administration was essentially undetectable in the brain and most other tissues, including blood and plasma, supporting the hypothesis that therapeutic activity occurs through peripheral chemosensory signaling rather than through systemic drug exposure. Preclinical electrophysiology studies further demonstrated that itruvone’s mechanism does not involve direct activation of GABA-A receptors in the brain, differentiating it from benzodiazepines and from the neurosteroid antidepressant brexanolone (allopregnanolone).

    The U.S. Food and Drug Administration has granted Fast Track designation for the development of itruvone as a potential treatment for MDD.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Tabernanthalog

    Non-hallucinogenic ibogaine analog and serotonergic psychoplastogen with 5-HT2A partial agonist activity promoting structural neuroplasticity

    A rationally designed, water-soluble, non-hallucinogenic analog of ibogaine engineered through function-oriented synthesis to retain psychoplastogenic neuroplasticity and preclinical antidepressant and anti-addictive activity while eliminating the cardiotoxicity and hallucinogenic liability of the parent alkaloid.

    Abstract

    Tabernanthalog (TBG, DLX-007) is a synthetic, water-soluble analog of the indole alkaloid ibogaine, first reported by Cameron et al. in a 2020 publication in Nature from the Olson laboratory at the University of California, Davis. The compound was engineered through function-oriented synthesis to isolate the therapeutic pharmacophore of ibogaine while eliminating two liabilities that have prevented clinical development of the parent alkaloid: blockade of the human ether-a-go-go-related gene (hERG) potassium channel (the basis of ibogaine-associated QT prolongation and fatal cardiac arrhythmia) and activation of hallucinogenic signaling cascades downstream of the serotonin 5-HT2A receptor. Tabernanthalog retains the capacity to promote rapid, sustained structural neuroplasticity in cortical neurons, including dendritic arborization and spinogenesis in the prefrontal cortex, through activation of the 5-HT2A receptor and downstream TrkB, mTOR, and AMPA receptor signaling pathways. A 2025 publication in Nature Neuroscience by Aarrestad et al. demonstrated that tabernanthalog achieves this neuroplasticity without inducing the immediate glutamate burst or the immediate early gene (IEG) activation that characterize classical hallucinogenic psychedelics, establishing a dissociation between psychoplastogenic structural remodeling and the acute transcriptional programs previously considered prerequisite. In behavioral pharmacology, tabernanthalog does not produce the mouse head-twitch response, the standard behavioral proxy for hallucinogenic activity, confirming its non-hallucinogenic profile. Preclinical efficacy has been demonstrated across multiple disease-relevant models: a single dose reduces immobility in the forced swim test (antidepressant-like activity); a single dose restores functional neural circuits, including dendritic spine density and sensory processing, disrupted by unpredictable mild stress in mice (Lu et al., Molecular Psychiatry 2021); a single dose reduces heroin self-administration in rats and alcohol binge drinking in mice; and tabernanthalog reduces motivation for both heroin and alcohol in a polydrug use model with effects persisting up to 14 days after treatment (Heinsbroek et al., 2023). The molecular pharmacology of tabernanthalog extends beyond 5-HT2A partial agonism to include antagonism at the 5-HT2B receptor, agonism at 5-HT1B, 5-HT1F, 5-HT2C, and 5-HT6 receptors, inhibition of monoamine oxidase A, activity at the alpha-2A adrenergic receptor and the serotonin transporter, and inhibition of alpha-7 and alpha-9/alpha-10 nicotinic acetylcholine receptors at low-micromolar concentrations. The compound does not interact significantly with opioid receptors, the NMDA receptor, or the hERG potassium channel. Tabernanthalog is prepared in a single synthetic step from commercially available precursors, is freely water-soluble as the fumarate salt, and has a molecular weight of 230.31 g/mol (free base). Despite strong preclinical validation and assignment of the development code DLX-007 by Delix Therapeutics, the compound has not entered human clinical trials as of May 2026; the company’s lead clinical candidate is the structurally related psychoplastogen zalsupindole (DLX-001). This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cycloastragenol

    Lanostane-type tetracyclic triterpenoid sapogenin with telomerase-activating, anti-inflammatory, and antioxidant activity

    A naturally occurring triterpenoid aglycone derived from Astragalus membranaceus, identified as the bioactive sapogenin of astragaloside IV and the principal small-molecule telomerase activator in the TA-65 formulation, with expanding preclinical evidence in anti-inflammatory, neuroprotective, cardioprotective, and anti-senescence applications.

    Abstract

    Cycloastragenol (CAG) is a lanostane-type tetracyclic triterpenoid sapogenin obtained by acid or enzymatic hydrolysis of astragaloside IV, the principal bioactive saponin of Astragalus membranaceus (Huangqi), a plant with extensive use in traditional Chinese medicine. The compound gained prominence following a systematic screen of natural product libraries at Geron Corporation in the early 2000s that identified it as a small-molecule activator of human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase. This discovery led to the development and commercialization of TA-65, a proprietary cycloastragenol-containing nutraceutical formulation marketed by T.A. Sciences for telomere health and anti-aging applications. The telomerase-activating mechanism involves upregulation of hTERT gene expression, enhanced nuclear localization of the hTERT protein via upregulation of the Hsp90 chaperone complex, and activation of the cAMP response element binding protein (CREB) signaling axis. At the cellular level, cycloastragenol activates telomerase in multiple cell types including peripheral blood mononuclear cells, CD4-positive and CD8-positive T lymphocytes, fibroblasts, and neuronal cells, with functional consequences including telomere elongation, reduced replicative senescence, and enhanced proliferative capacity. A 2016 randomized, double-blind, placebo-controlled clinical trial of TA-65 in 117 cytomegalovirus-positive subjects aged 53 to 87 years demonstrated dose-dependent telomere lengthening in the low-dose group (530 plus or minus 180 base pairs; p equals 0.005) over 12 months, with the placebo group losing telomere length (290 plus or minus 100 base pairs; p equals 0.01). The compound additionally exhibits pharmacological activities independent of the telomerase mechanism. Preclinical studies have characterized anti-inflammatory effects through inhibition of NF-kappaB signaling and pyroptosis pathways; neuroprotective activity through upregulation of SIRT1 expression, activation of the Nrf2/HO-1 pathway, and promotion of BDNF/p-TrkB/CREB signaling; cardioprotective effects through promotion of myocardial autophagy via inhibition of AKT1-RPS6KB1 signaling; anti-fibrotic activity in hepatic and pulmonary models; and antioxidant effects through activation of the Nrf2/ARE transcriptional pathway. Pharmacokinetics in the rat model show oral bioavailability of approximately 25.7 percent following acid hydrolysis-mediated absorption, substantially higher than the parent compound astragaloside IV (2.2 percent), with extensive first-pass hepatic metabolism limiting systemic exposure. In human liver microsomes, only 8.2 percent of cycloastragenol remained after 30 minutes of incubation, indicating rapid phase I metabolism. Clinical safety data from TA-65 studies over 12 months of supplementation report no serious adverse events, with mild gastrointestinal discomfort as the principal dose-dependent adverse effect. The theoretical concern of telomerase activation promoting oncogenesis has not been substantiated in preclinical cancer bioassays or in clinical observation, though the mechanism warrants continued surveillance. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.